Akash Mukherjee, MD
Hematology & Oncology · Cincinnati, OHNPI 1285981498
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $119,965 of the $131,798 with a category attached, or 91.0%. 31 manufacturers reported payments, led by Gilead at 56.2% of the total. Among hematology & oncology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $878.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$74K
- Beigene USA, Inc.$41K
- Beone Medicines USA, Inc.$11K
- ADC Therapeutics America, Inc.$4K
- Astellas Pharma US Inc$282
- Novartis$140
- plus $1K from 25 others
Across 146 payments — averaging $2609.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$173K
- Janssen Research & Development, LLC$95K
- Epizyme, Inc.$69K
- Bristol Myers Squibb$13K
- E.r. Squibb & Sons, L.L.C.$10K
- Incyte Corporation$9K
- plus $11K from 3 others
What the payments were for
- Consulting fees$2,5252%
- Speaking & faculty fees$119,96591%
- Travel & lodging$5,3654%
- Food & beverage$3,6963%
- Education$2480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 48 | $74,084 |
| Beigene USA, Inc. | 22 | $41,470 |
| Beone Medicines USA, Inc. | 9 | $10,891 |
| ADC Therapeutics America, Inc. | 6 | $3,719 |
| Astellas Pharma US Inc | 6 | $282 |
| Novartis | 7 | $140 |
| AbbVie | 4 | $113 |
| Johnson & Johnson | 6 | $112 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $112 |
| Cumberland Pharmaceuticals, Inc. | 3 | $92 |
| Daiichi Sankyo Inc. | 5 | $88 |
| GSK | 4 | $86 |
| Pfizer | 4 | $74 |
| Sanofi-aventis U.S. LLC | 3 | $63 |
| Azurity Pharmaceuticals, Inc. | 3 | $47 |
| Incyte Corporation | 2 | $44 |
| Invivyd Inc | 2 | $42 |
| Genentech USA, Inc. | 2 | $38 |
| Shorla Oncology Inc. | 1 | $34 |
| Syndax Pharmaceuticals, Inc. | 1 | $33 |
| Sanofi | 1 | $31 |
| Adaptive Biotechnologies Corporation | 1 | $30 |
| Sobi, Inc | 1 | $28 |
| Rigel Pharmaceuticals, Inc. | 1 | $28 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Taiho Oncology, Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Legend Biotech USA Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$131,798 in reported general payments places this provider in the 90th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 31 | $442,119 |
| RevlimidLenalidomide | 22 | $353,018 |
| RezurockBelumosudil Mesylate | 12 | $311,777 |
| VenclextaVenetoclax | 37 | $219,064 |
| NinlaroIxazomib Citrate | 13 | $142,282 |
| Lenalidomide | 11 | $120,252 |
| EliquisApixaban | 46 | $29,305 |
| Tacrolimus | 28 | $6,059 |
| ValacyclovirValacyclovir Hcl | 90 | $5,673 |
| Ursodiol | 25 | $3,359 |
| Fluconazole | 54 | $1,476 |
| Ondansetron Hcl | 16 | $1,460 |
| Acyclovir | 107 | $1,081 |
| Dapsone | 15 | $935 |
| Levofloxacin | 77 | $883 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $41,470 | $442,11931 claims |
| Bristol Myers SquibbRevlimid | $18 | $353,01822 claims |
| Sanofi-aventis U.S. LLCRezurock | $63 | $311,77712 claims |
| AbbVieVenclexta | $113 | $219,06437 claims |
| PfizerEliquis | $74 | $29,30546 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cincinnati
- David WaterhouseCincinnati$1.3M
- Mark AndolinaCincinnati$402K
- James EssellCincinnati$214K
- Davendra SohalCincinnati$112K
- Edward FaberCincinnati$72K
- Alexander StarodubCincinnati$72K
- Brittaney Belle GordonCincinnati$53K
- Soumit BasuCincinnati$46K
- Trisha Wise-DraperCincinnati$44K
- Emily CurranCincinnati$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.